Recurrent Skin Cancer Clinical Trial
Official title:
A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCCs)
The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.
PRIMARY OBJECTIVES:
I. The percent reduction in surgical defect area/size surrounding BCC tumor pre and
post-vismodegib.
SECONDARY OBJECTIVES:
I. Recurrence rate post treatment II. Safety, tolerability and percent drop-out after 3 vs. 6
months of vismodegib in otherwise healthy patients.
OUTLINE:
Patients receive vismodegib orally (PO) once daily (QD) for up to 3 months if the initial BCC
size is < 2 cm and superficial or for up to 6 months if the initial BCC size is >= 2 cm or
non-superficial. After completion of vismodegib treatment, patients undergo Mohs surgery.
After completion of study treatment, patients are followed up for an average of 24 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00563290 -
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Terminated |
NCT01823679 -
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
|
Phase 2 | |
| Completed |
NCT01292668 -
Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer
|
Phase 1 | |
| Completed |
NCT00126555 -
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
|
Phase 2 | |
| Completed |
NCT00089180 -
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
|
Phase 2 | |
| Completed |
NCT02324608 -
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
|
N/A | |
| Terminated |
NCT02303041 -
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT01465815 -
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
|
Phase 1/Phase 2 | |
| Completed |
NCT01791894 -
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02507076 -
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
|
N/A |